Gove S, 1997. Integrated management of childhood illness by outpatient health workers: technical basis and overview. The WHO Working Group on Guidelines for Integrated Management of the Sick Child. Bull World Health Organ 75 (Suppl 1): 7–24.
World Health Organization, 2005. Pocket Book of Hospital Care for Children: Guidelines for the Management of Common Illnesses with Limited Resources. Geneva: World Health Organization.
World Health Organization, 2000. Management of the Child with a Serious Infection or Severe Malnutrition: Guidelines for Care at the First-Referral Level in Developing Countries. Geneva: World Health Organization. Available at: http://www.who.int/maternal_child_adolescent/documents/fch_cah_00_1/en/. Accessed April 16, 2014.
World Health Organization, 2011. IMAI District Clinician Manual: Hospital Care for Adolescents and Adults. Geneva: World Health Organization. Available at: http://www.who.int/hiv/pub/imai/imai2011/en/. Accessed February 11, 2013.
Bassat Q, Machevo S, O'Callaghan-Gordo C, Sigauque B, Morais L, Diez-Padrisa N, Ribo JL, Mandomando I, Nhampossa T, Ayala E, Sanz S, Weber M, Roca A, Alonso PL, 2011. Distinguishing malaria from severe pneumonia among hospitalized children who fulfilled integrated management of childhood illness criteria for both diseases: a hospital-based study in Mozambique. Am J Trop Med Hyg 85: 626–634.
Berkley JA, Maitland K, Mwangi I, Ngetsa C, Mwarumba S, Lowe BS, Newton CR, Marsh K, Scott JA, English M, 2005. Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ 330: 995.
Nadjm B, Amos B, Mtove G, Ostermann J, Chonya S, Wangai H, Kimera J, Msuya W, Mtei F, Dekker D, Malahiyo R, Olomi R, Crump JA, Whitty CJ, Reyburn H, 2010. WHO guidelines for antimicrobial treatment in children admitted to hospital in an area of intense Plasmodium falciparum transmission: prospective study. BMJ 340: c1350.
Clifton DC, Ramadhani HO, Msuya LJ, Njau BN, Kinabo GD, Buchanan AM, Crump JA, 2012. Predicting mortality for pediatric inpatients where malaria is uncommon. Arch Dis Child 97: 889–894.
Crump JA, Morrissey AB, Nicholson WL, Massung RF, Stoddard RA, Galloway RL, Ooi EE, Maro VP, Saganda W, Kinabo GD, Muiruri C, Bartlett JA, 2013. Etiology of severe non-malaria febrile illness in northern Tanzania: a prospective cohort study. PLoS Negl Trop Dis 7: e2324.
Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, Yang LY, Chow SC, Morpeth SC, Reyburn H, Njau BN, Shaw AV, Diefenthal HC, Shao JF, Bartlett JA, Maro VP, 2011. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania. Clin Infect Dis 52: 341–348.
Crump JA, Ramadhani HO, Morrissey AB, Msuya LJ, Yang LY, Chow SC, Morpeth SC, Reyburn H, Njau BN, Shaw AV, Diefenthal HC, Bartlett JA, Shao JF, Schimana W, Cunningham CK, Kinabo GD, 2011. Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected children and infants in northern Tanzania. Trop Med Int Health 16: 830–837.
National Bureau of Statistics, 2013. 2012 Population and Housing Census. Dar Es Salaam: United Republic of Tanzania. Available at: http://www.nbs.go.tz/sensa/new.html. Accessed December 12, 2013.
National Bureau of Statistics, 2005. Tanzania Demographic and Health Survey 2004–2005. Dar es Salaam: United Republic of Tanzania. Available at: http://nbs.go.tz/tnada/index.php/catalog/8. Accessed December 19, 2013.
Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, Noor AM, Kabaria CW, Manh BH, Elyazar IR, Brooker S, Smith DL, Moyeed RA, Snow RW, 2009. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 6: e1000048.
National Bureau of Statistics, 2008. Tanzania HIV/AIDS and Malaria Indicator Survey 2007–2008. Dar es Salaam: United Republic of Tanzania. Available at: www.nbs.go.tz/tnada/index.php/catalog/9/download/16. Accessed December 27, 2013.
Prabhu M, Nicholson WL, Roche AJ, Kersh GJ, Fitzpatrick KA, Oliver LD, Massung RF, Morrissey AB, Bartlett JA, Onyango JJ, Maro VP, Kinabo GD, Saganda W, Crump JA, 2011. Q fever, spotted fever group, and typhus group rickettsioses among hospitalized febrile patients in northern Tanzania. Clin Infect Dis 53: e8–e15.
Biggs HM, Bui DM, Galloway RL, Stoddard RA, Shadomy SV, Morrissey AB, Bartlett JA, Onyango JJ, Maro VP, Kinabo GD, Saganda W, Crump JA, 2011. Leptospirosis among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg 85: 275–281.
Bouley AJ, Biggs HM, Stoddard RA, Morrissey AB, Bartlett JA, Afwamba IA, Maro VP, Kinabo GD, Saganda W, Cleaveland S, Crump JA, 2012. Brucellosis among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg 87: 1105–1111.
Hertz JT, Munishi OM, Ooi EE, Howe S, Lim WY, Chow A, Morrissey AB, Bartlett JA, Onyango JJ, Maro VP, Kinabo GD, Saganda W, Gubler DJ, Crump JA, 2012. Chikungunya and dengue fever among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg 86: 171–177.
Lofgren SM, Kirsch EJ, Maro VP, Morrissey AB, Msuya LJ, Kinabo GD, Saganda W, Diefenthal HC, Ramadhani HO, Wheat LJ, Crump JA, 2012. Histoplasmosis among hospitalized febrile patients in northern Tanzania. Trans R Soc Trop Med Hyg 106: 504–507.
Feldmesser M, Harris C, Reichberg S, Khan S, Casadevall A, 1996. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis 23: 827–830.
Crump JA, Ramadhani HO, Morrissey AB, Saganda W, Mwako MS, Yang LY, Chow SC, Njau BN, Mushi GS, Maro VP, Reller LB, Bartlett JA, 2012. Bacteremic disseminated tuberculosis in sub-Saharan Africa: a prospective cohort study. Clin Infect Dis 55: 242–250.
Centers for Disease Control and Prevention, 2012. Case Definitions: Nationally Notifiable Diseases and Conditions. Atlanta, GA: CDC. Available at: http://wwwn.cdc.gov/nndss/document/2012_Case%20Definitions.pdf. Accessed December 27, 2012.
Wongsrichanalai C, Murray CK, Gray M, Miller RS, McDaniel P, Liao WJ, Pickard AL, Magill AJ, 2003. Co-infection with malaria and leptospirosis. Am J Trop Med Hyg 68: 583–585.
Russell KL, Montiel Gonzalez MA, Watts DM, Lagos-Figueroa RC, Chauca G, Ore M, Gonzalez JE, Moron C, Tesh RB, Vinetz JM, 2003. An outbreak of leptospirosis among Peruvian military recruits. Am J Trop Med Hyg 69: 53–57.
Molyneux ME, Taylor TE, Wirima JJ, Borgstein A, 1989. Clinical features and prognostic indicators in pediatric cerebral malaria: a study of 131 comatose Malawian children. QJM 71: 441–459.
Performance Standards for Antimicrobial Susceptibility Testing, 2013. 23rd Informational Supplement (M100-S23). Wayne, PA: Clinical and Laboratory Standards Institute.
Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC, 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 50: 291–322.
Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, 2007. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 45: 807–825.
Ressner RA, Griffith ME, Beckius ML, Pimentel G, Miller RS, Mende K, Fraser SL, Galloway RL, Hospenthal DR, Murray CK, 2008. Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira. Antimicrob Agents Chemother 52: 2750–2754.
Rolain JM, Maurin M, Vestris G, Raoult D, 1998. In vitro susceptibilities of 27 rickettsiae to 13 antimicrobials. Antimicrob Agents Chemother 42: 1537–1541.
Rolain JM, Stuhl L, Maurin M, Raoult D, 2002. Evaluation of antibiotic susceptibilities of three rickettsial species including Rickettsia felis by a quantitative PCR DNA assay. Antimicrob Agents Chemother 46: 2747–2751.
Raoult D, Torres H, Drancourt M, 1991. Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii. Antimicrob Agents Chemother 35: 2070–2077.
Munoz-Espin T, Lopez-Pares P, Espejo-Arenas E, Font-Creus B, Martinez-Vila I, Traveria-Casanova J, Segura-Porta F, Bella-Cueto F, 1986. Erythromycin versus tetracycline for treatment of Mediterranean spotted fever. Arch Dis Child 61: 1027–1029.
Meloni G, Meloni T, 1996. Azithromycin vs. doxycycline for Mediterranean spotted fever. Pediatr Infect Dis J 15: 1042–1044.
Dijkstra F, Riphagen-Dalhuisen J, Wijers N, Hak E, Van der Sande MA, Morroy G, Schneeberger PM, Schimmer B, Notermans DW, Van der Hoek W, 2011. Antibiotic therapy for acute Q fever in The Netherlands in 2007 and 2008 and its relation to hospitalization. Epidemiol Infect 139: 1332–1341.
Gikas A, Kofteridis DP, Manios A, Pediaditis J, Tselentis Y, 2001. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 45: 3644–3646.
Petti CA, Polage CR, Quinn TC, Ronald AR, Sande MA, 2006. Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis 42: 377–382.
Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, Saganda K, Shao J, Kitua A, Olomi R, Greenwood BM, Whitty CJ, 2004. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 329: 1212.
Bassat Q, Ordi J, Vila J, Ismail MR, Carrilho C, Lacerda M, Munguambe K, Odhiambo F, Lell B, Sow S, Bhutta ZA, Rabinovich NR, Alonso PL, Menéndez C, 2013. Development of a post-mortem procedure to reduce the uncertainty regarding causes of death in developing countries. Lancet Global Health 1: e125–e126.
Ordi J, Ismail MR, Carrilho C, Romagosa C, Osman N, Machungo F, Bombi JA, Balasch J, Alonso PL, Menendez C, 2009. Clinico-pathological discrepancies in the diagnosis of causes of maternal death in sub-Saharan Africa: retrospective analysis. PLoS Med 6: e1000036.
Ministry of Health and Social Welfare, 2011. National Bureau of Statistics. National AIDS Control Programme HIV/AIDS/STI Surveillance Report Number 22. Dar es Salaam: United Republic of Tanzania. Available at: http://www.nacp.go.tz/site/download. Accessed July 30, 2014.
Tanzania Commission for AIDS, 2013. National HIV and AIDS Response Report 2012. Dar es Salaam: United Republic of Tanzania. Available at: http://www.tacaids.go.tz. Accessed July 30, 2014.
|Past two years||Past Year||Past 30 Days|
|Full Text Views||444||139||6|
We describe the laboratory-confirmed etiologies of illness among participants in a hospital-based febrile illness cohort study in northern Tanzania who retrospectively met Integrated Management of Adolescent and Adult Illness District Clinician Manual (IMAI) criteria for septic shock, severe respiratory distress without shock, and severe pneumonia, and compare these etiologies against commonly used antimicrobials, including IMAI recommendations for emergency antibacterials (ceftriaxone or ampicillin plus gentamicin) and IMAI first-line recommendations for severe pneumonia (ceftriaxone and a macrolide). Among 423 participants hospitalized with febrile illness, there were 25 septic shock, 37 severe respiratory distress without shock, and 109 severe pneumonia cases. Ceftriaxone had the highest potential utility of all antimicrobials assessed, with responsive etiologies in 12 (48%) septic shock, 5 (14%) severe respiratory distress without shock, and 19 (17%) severe pneumonia illnesses. For each syndrome 17–27% of participants had etiologic diagnoses that would be non-responsive to ceftriaxone, but responsive to other available antimicrobial regimens including amphotericin for cryptococcosis and histoplasmosis; anti-tuberculosis therapy for bacteremic disseminated tuberculosis; or tetracycline therapy for rickettsioses and Q fever. We conclude that although empiric ceftriaxone is appropriate in our setting, etiologies not explicitly addressed in IMAI guidance for these syndromes, such as cryptococcosis, histoplasmosis, and tetracycline-responsive bacterial infections, were common.
Financial support: Funding support received for this work includes the International Studies on AIDS Associated Co-infections (ISAAC) award, a United States National Institutes of Health (NIH) funded program (U01 AI062563). Investigator support was received from NIH awards ISAAC (to J.A.C., V.P.M., J.A.B.); AIDS International Training and Research Program (D43 PA-03-018 to J.A.C., V.P.M., J.A.B.; D43 TW009595 to J.A.B); Duke Clinical Trials Unit and Clinical Research Sites (U01 AI069484 to J.A.C., V.P.M., J.A.B.); the Center for HIV/AIDS Vaccine Immunology (U01 AI067854 to J.A.C., J.A.B.); the joint NIH-NSF Ecology and Evolution of Infectious Disease program and the UK Economic and Social Research Council and Biotechnology and Biological Sciences Research Council (R01 TW009237 to J.A.C., V.P.M.); and the Fogarty International Center Global Health Fellowship Program R25TW009343 (M.P.R.). Investigator support was also received from Health Resources and Services Administration T84HA21123 (J.A.B.).
Disclosure: Presented in part at the 63rd American Society of Tropical Medicine and Hygiene annual meeting, New Orleans, LA, 2–6 November 2014, abstract 1881.
Authors' addresses: Matthew P. Rubach, Department of Pathology, University of Utah, Salt Lake City, UT, E-mail: firstname.lastname@example.org. Venance P. Maro, Department of Internal Medicine, Kilimanjaro Christian Medical Centre, Moshi, Tanzania, E-mail: email@example.com. John A. Bartlett, Department of Internal Medicine, Duke University, Durham, NC, E-mail: firstname.lastname@example.org. John A. Crump, Department of Medicine, Duke University, Durham, NC, E-mail: email@example.com.